Before the autoimmune disease was diagnosed, Teresa Kariuki had lost her legs to it. She thought she would die but she lived ...

The multi-location study aimed to evaluate the efficacy, safety, and tolerability of iptacopan (LNP023) in addition to standard-of-care treatment in lupus.

Biogen’s new drug felzartamab is being tested to treat antibody-mediated rejection, a condition that happens when a kidney transplant patient’s immune system turns on the new organ and attacks it as ...

Novartis (NVS) has terminated a mid-stage trial for its oral Factor B inhibitor Fabhalta (iptacopan) in lupus nephritis, an inflammatory condition affecting the kidneys, because of strategic ...

Novartis has ended a mid-stage trial of Fabhalta for lupus nephritis, citing strategic considerations. The clinical-trial registry offered no further explanation and did not indicate whether safety or ...

Swiss drugmaker Novartis has terminated a mid-stage study testing its drug Fabhalta ​in patients with a serious ‌kidney ...

Background SLE is a complex autoimmune condition requiring evaluation across disease activity, permanent damage and ...

Judge Dianne Jones of Dallas County Court on Friday affirmed the July verdict of $604,025,000 handed down in July against C.H. Robinson (NASDAQ: CHRW) as a result of a fatal accident that killed three ...

The hope with CAR T cell therapies for autoimmune disease is that they can reset the immune system and induce deep remission. But recent trial pauses have renewed concerns about safety, patient ...

CAR-T cell therapy, approved for some blood cancers, is being studied for lupus, MS, and scleroderma. Yale Medicine experts ...

Absence of branched N-glycans on γδ T cells acts as a peripheral signal that amplifies a type 3/IL-17A response in ...